Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
TEL AVIV, Israel, Feb. 01, 2016 -- VBL Therapeutics (NASDAQ:VBLT), announced today that Chief Executive Officer, Dror Harats, M.D., will provide a corporate overview and business update at the BIO CEO & Investor Conference.
| Presentation Details: | |
| Title: | The 18th Annual BIO CEO & Investor Conference |
| Date: | February 9th, 2016 |
| Time: | 11:30-11:55 AM |
| Location: | The Waldorf Astoria New York |
| Webcast: | http://www.veracast.com/webcasts/bio/ceoinvestor2016/47215257222.cfm |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma (rGBM), an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics' pivotal Phase 3 GLOBE trial of VB-111 in rGBM is ongoing under a special protocol assessment granted by the FDA.
INVESTOR CONTACT: Michael Rice, Founding Partner LifeSci Advisors, LLC 646-597-6979
